case_images: PMC7325976_01
case_images: Computed tomography (CT) scans before (A) and after (B) afatinib therapy.
case_images: fonc-10-00867-g0001.jpg
case_images: PMC7325976_01_fonc-10-00867-g0001.jpg
case_images: F1
case_images: A mass (2.3 x 1.8 cm) in the right lower lung was observed by computed tomography (CT) scan (Figure 1A). China) (Figure 3), and PD-L1 staining was not done. Therefore, he underwent oral afatinib treatment (30 mg qd). Afterwards, the patient showed a stable tumor response to afatinib (1.9 x 1.4 cm) (Figure 1B). Besides, there were no adverse events, including gastrointestinal reactions, hepatic and renal function, and cardiac damage. Currently, the disease is stable and treatment with afatinib continues for 10 months.
case_images: Hematoxylin and eosin (H&E) staining of lung biopsy showed a typical morphology for adenocarcinoma cells (H&E x 100).
case_images: fonc-10-00867-g0002.jpg
case_images: PMC7325976_01_fonc-10-00867-g0002.jpg
case_images: F2
case_images: We detected a typical morphology for adenocarcinoma cells by hematoxylin and eosin (H&E) staining (Figure 2).
case_images: The EGFR-KDD is an oncogenic EGFR alteration. (A) The Integrative Genomics Viewer snapshot of paired NGS reads of tumor and matched blood. (B) Schematic representation of EGFR-KDD depicting the genetic and protein domain structures. ECD, extracellular domain; TM, transmembrane domain; KD1, first kinase domain; KD2, second kinase domain; C-term, carboxyl terminus. Blue, EGFR exons 18-25 #1; orange, EGFR exons 18-25 #2.
case_images: fonc-10-00867-g0003.jpg
case_images: PMC7325976_01_fonc-10-00867-g0003.jpg
case_images: F3
case_images: China) (Figure 3), and PD-L1 staining was not done. Therefore, he underwent oral afatinib treatment (30 mg qd). Afterwards, the patient showed a stable tumor response to afatinib (1.9 x 1.4 cm) (Figure 1B). Besides, there were no adverse events, including gastrointestinal reactions, hepatic and renal function, and cardiac damage. Currently, the disease is stable and treatment with afatinib continues for 10 months.